RT Journal Article
SR Electronic
T1 A simplified SARS-CoV-2 pseudovirus neutralization assay
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.03.12.21253435
DO 10.1101/2021.03.12.21253435
A1 Donofrio, Gaetano
A1 Franceschi, Valentina
A1 Macchi, Francesca
A1 Russo, Luca
A1 Rocci, Anna
A1 Marchica, Valentina
A1 Costa, Federica
A1 Giuliani, Nicola
A1 Ferrari, Carlo
A1 Missale, Gabriele
YR 2021
UL http://medrxiv.org/content/early/2021/03/12/2021.03.12.21253435.abstract
AB COVID-19 is an ongoing pandemic caused by the highly infectious coronavirus SARS-CoV-2 that is engaging worldwide scientific research to find a timely and effective eradication strategy. Great efforts have been put into anti-COVID-19 vaccine generation in an effort to protect the world population and block SARS-CoV-2 spread. To validate the protective efficacy of the vaccination campaign and effectively control the pandemy, it is necessary to quantify the neutralizing antibodies induction by vaccination, since they have been established to be a correlate of protection. In this work a SARS-CoV-2 pseudovirus neutralization assay, based on a replication incompetent lentivirus expressing an adapted form of CoV-2 S protein and an ACE2/TMPRSS2 stably expressing cell line, have been minimized in term of protocol steps without loss of accuracy. The goal of the present simplified neutralization system is to improve SARS-CoV-2 vaccination campaign by means of an easy and accessible approach to be performed in any medical laboratory, maintaining the sensitivity and quantitative reliability of classical serum neutralization assays. Further this assay can be easily adapted to different coronaviruses variants by simply modifying the pseudotyping vector.Competing Interest StatementThe authors have declared no competing interest.Funding StatementResidual founding from grants unrelated to the present work topic.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the local ethical committee (Comitato Etico Area Vasta Emilia Nord (AVEN), Italy). All participants gave written informed consent to participate in the study.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are available